Sunday November 22 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

karo bio

KARO BIO IS AN ESTABLISHED GLOBAL LEADER IN THE FIELD OF NUCLEAR RECEPTOR RESEARCH AND DRUG DISCOVERY.

Karo Bio is committed to finding new and better pharmaceuticals that can effectively treat serious diseases without the deleterious side effects commonly experienced with today's drugs.



Karo Bio is a drug discovery company focusing its research on the discovery and pre-clinical phases of drug development. Research is conducted primarily in the area of nuclear receptors.



Nuclear receptors are proteins in the cell nucleus that act as receivers for a number of key hormones that enable the essential regulation of organs in the body. Through the understanding of nuclear receptors in drug design, new tissue selective drugs can be developed that have fewer or no side effects.



Through ongoing partnerships with outstanding academic and research institutions, such as the Karolinska Institute, home of the Nobel Prize, Karo Bio continues to be at the forefront of new discoveries to advance the Company's work with nuclear receptors and other research endeavors. With the current programs underway, Karo Bio is diligently working to discover and develop drugs for important therapeutic areas such as women's health, diabetes, inflammatory disease, obesity, cardiovascular disease, and atherosclerosis.



In addition to nuclear receptor research and development, Karo Bio also offers a novel approach to target validation and high-throughput screening with proprietary BioKey® technology. This proteomics-based drug discovery technology is ideal for the development of screens for targets of unknown function and for targets difficult to screen by traditional methods. The proprietary BioKey® technology is used for internal discovery programs and collaborative out-licensing agreements with pharmaceutical and biotechnology companies.


Contact Details:
Novum 141 57
Huddinge
Huddinge
141 57
Sweden
Tel:++46 8 608 6074
Fax:++46 774 8261
Email:bo.carlsson@karobio.se
WWW:

www.karobio.se/




Recent Publications by karo bio:

Underlying mechanisms mediating the antidepressant effects of estrogens.
Background: There is an increased risk for depressive symptoms and...
11th November, 2009
Karo Bio AB, Novum SE-141 57, Huddinge, Sweden. Biochim Biophys Acta. 2009 Nov 6.
DOI Direct Link
ERbeta a Novel Estrogen Receptor Offers the Potential for New Drug Development.
There is increasing interest in developing better drugs for improving the...
15th April, 2008
Karo Bio AB, Huddinge, Sweden. Trends Endocrinol Metab. 1998 Dec;9(10):387-95.
The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans.
Atherosclerotic cardiovascular disease is a major problem despite the...
7th February, 2008
Karo Bio AB, Novum Research Park, S-141 57 Huddinge, Sweden. Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):663-7. Epub 2007 Dec 26.
DOI Direct Link
Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141.
Based on the scaffold of the pharmacologically selective thyromimetic 2b,...
2nd October, 2007
Karo Bio AB, Novum, Huddinge S-141 57, Sweden. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4131-4. Epub 2007 May 21.
DOI Direct Link
Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity.
Based on the concept of 'indirect antagonism' of nuclear receptors, a...
26th July, 2007
Karo Bio AB, Bioorg Med Chem Lett. 2007 Apr 1;17(7):2018-21. Epub 2007 Jan 13.
DOI Direct Link

View more karo bio research publications.

BioNews Results for karo bio:

Prospectus For Karo Bio??s Rights Issue Now Available
Therapeutics Daily:  Nov 11 2009 11:11AM Matching: karo bio
Pressrelease From The Extraordinary General Meeting Of Karo Bio Ab (publ)
Therapeutics Daily:  Nov 11 2009 10:17AM Matching: karo bio
Prospectus for Karo Bio AB's Rights Issue Now Available
BioSpace:  Nov 11 2009 7:44PM Matching: karo bio
Karo Bio??s Nominating Committee For The Annual General Meeting 2010 Appointed
Therapeutics Daily:  Nov 10 2009 11:18AM Matching: karo bio
Karo Bio's Nominating Committee For The Annual General Meeting 2010 Appointed
Pharma Live:  Nov 10 2009 5:03PM Matching: karo bio
Promote your company here: BioNewsCast - Press Release Distribution

View more karo bio news.

karo bio Clinical Trials:

Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia

karo bio Patents:

US Patent No.Title
7521439 Glucocorticoid receptor ligands for the treatment of metabolic disorders
6617114 Identification of drug complementary combinatorial libraries
6525188 Nuclear retinoic acid co-receptor
6492424 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
6468975 Liver specific bile acid derivatives of the glucocorticoid antagonist RU486

View more karo bio patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 430 times since April 2007, the link to the organisation's website has been followed 55 times

Search for more companies in Huddinge

Search for more companies in Huddinge



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for karo bio

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.